Skip to main content
. 2014 Dec 9;23(2):330–338. doi: 10.1038/mt.2014.219

Figure 6.

Figure 6

In vivo antitumor activity of NK-92/5.28.z cells. (a) To investigate antitumor activity, NSG mice were intravenously injected with Renca-lacZ/ErbB2 renal cell carcinoma cells. Then, animals were treated twice by i.v. injection of parental NK-92 or clonal NK-92/5.28.z cells at days 1 and 3 after tumor cell injection. Control mice received PBS. Four weeks after tumor challenge, lungs were excised and tumor nodules on the lung surface were counted. Mean values ± SEM are shown; n = 5. ns, P > 0.05; *P < 0.05. (b) Representative images of lungs at day 28 from animals treated with NK-92 or NK-92/5.28.z cells. (c) To evaluate the effect of multiple treatments, NSG mice injected with Renca-lacZ/ErbB2 cells were treated with NK-92 or NK-92/5.28.z cells twice as described in panel a (n = 5), or four times at days 1, 3, 6, and 8 (n = 4). Data points for each animal and mean values ± SEM are shown. **P < 0.01. (d) In a separate experiment, NSG mice injected with Renca-lacZ/ErbB2 cells were treated twice as described in panel a with nonirradiated NK-92 or NK-92/5.28.z cells, or NK-92/5.28.z cells irradiated with 10 Gy as indicated. Mean values ± SEM are shown; n = 5. **P < 0.01.